The European Medicine Agency (EMA) supports national authorities who may decide on possible early use of Paxlovid prior to marketing authorization, for example in emergency use settings, in the light of rising rates of infection and deaths due to COVID-19 across the EU.
The European Medicine Agency (EMA) supports national authorities who may decide on possible early use of Paxlovid prior to marketing authorization, for example in emergency use settings, in the light of rising rates of infection and deaths due to COVID-19 across the EU.
Seems like great news for Europe!
https://www.ema.europa.eu/en/news/ema-issues-advice-use-paxlovid-pf-07321332-ritonavir-treatment-covid-19